Cited by 188Down syndrome and intellectual disability researchNeurogenesis and neuroplasticity mechanismsGenetics and Neurodevelopmental Disorders

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome

Open access

Bianchi, P., Ciani, E., Guidi, S., Trazzi, S., Felice, D., Grossi, G., Fernandez, M., Giuliani, A., Calza, L., Bartesaghi, R.·2010·Journal of Neuroscience

DOI 10.1523/jneurosci.0534-10.2010PMC PMC6632890

Open this paper in CoChat — free account Open PDF

Abstract

Down syndrome (DS) is a genetic pathology characterized by intellectual disability and brain hypotrophy. Widespread neurogenesis impairment characterizes the fetal and neonatal DS brain, strongly suggesting that this defect may be a major determinant of mental retardation. Our goal was to establish, in a mouse model for DS, whether early pharmacotherapy improves neurogenesis and cognitive behavior. Neonate Ts65Dn mice were treated from postnatal day (P) 3 to P15 with fluoxetine, an antidepressant that inhibits serotonin (5-HT) reuptake and increases proliferation in the adult Ts65Dn mouse (Clark et al., 2006). On P15, they received a BrdU injection and were killed after either 2 h or 1 month. Results showed that P15 Ts65Dn mice had notably defective proliferation in the hippocampal dentate gyrus, subventricular zone, striatum, and neocortex and that proliferation was completely rescued by fluoxetine. In the hippocampus of untreated P15 Ts65Dn mice, we found normal 5-HT levels but a lower expression of 5-HT1A receptors and brain-derived neurotrophic factor (BDNF). In Ts65Dn mice, fluoxetine treatment restored the expression of 5-HT1A receptors and BDNF. One month after cessation of treatment, there were more surviving cells in the dentate gyrus of Ts65Dn mice, more cells with a neuronal phenotype, more proliferating precursors, and more granule cells. These animals were tested for contextual fear conditioning, a hippocampus-dependent memory task, and exhibited a complete recovery of memory performance. Results show that early pharmacotherapy with a drug usable by humans can correct neurogenesis and behavioral impairment in a model for DS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1523/jneurosci.0534-10.2010

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Chromosome 21-derived MicroRNAs Provide an Etiological Basis for Aberrant Protein Expression in Human Down Syndrome Brains
Kuhn, D. E., Nuovo, G. J., Terry, A. V., Martin, M. M., Malana, G. E., Sansom, S. E., Pleister, A. P., Beck, W. D., Head, E., Feldman, D. S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033407 · Cited by 121
Retracted
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999) · Nature Genetics · doi:10.1038/13810 · Cited by 4,990
The Ki-67 protein: From the known and the unknown
Scholzen, T. E., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3 · Cited by 4,707
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.
Phillips, R. G., & LeDoux, J. E. (1992) · Behavioral Neuroscience · doi:10.1037/0735-7044.106.2.274 · Cited by 3,292
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription
Chahrour, M., Jung, S. Y., Shaw, C., Zhou, X., Wong, S. T. C., Qin, J., & Zoghbi, H. Y. (2008) · Science · doi:10.1126/science.1153252 · Cited by 1,823
Multipotent CNS Stem Cells Are Present in the Adult Mammalian Spinal Cord and Ventricular Neuroaxis
Weiss, S., Dunne, C., Hewson, J., Wohl, C. A., Wheatley, M., Peterson, A. C., & Reynolds, B. A. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-23-07599.1996 · Cited by 1,219

Show all 62 references

Sorted by citations

Items 101–185 of 185

G-Protein-Associated Signal Transduction Processes Are Restored after Postweaning Environmental Enrichment in Ts65Dn, a Down Syndrome Mouse Model
Baamonde, C., Martínez‐Cué, C., Flórez, J., & Dierssen, M. (2011) · Developmental Neuroscience · doi:10.1159/000329425 · Cited by 23
BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients
Tlili, A., Hoischen, A., Ripoll, C., Benabou, E., Badel, A., Ronan, A., Touraine, R. L., Grattau, Y., Stora, S., van Bon, B. W. M., et al. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8284-7 · Cited by 22
Maternal choline supplementation protects against age-associated cholinergic and GABAergic basal forebrain neuron degeneration in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease
Gautier, M. K., Kelley, C. M., Lee, S. H., Alldred, M. J., McDaid, J., Mufson, E. J., Stutzmann, G. E., & Ginsberg, S. D. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106332 · Cited by 21
Developmental excitatory-to-inhibitory GABA polarity switch is delayed in Ts65Dn mice, a genetic model of Down syndrome
Lysenko, L. V., Kim, J., Madamba, F., Tyrtyshnaia, A. A., Ruparelia, A., & Kleschevnikov, A. M. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.005 · Cited by 21
Subicular hypotrophy in fetuses with Down syndrome and in the Ts65Dn model of Down syndrome
Stagni, F., Giacomini, A., Emili, M., Uguagliati, B., Bonasoni, M. P., Bartesaghi, R., & Guidi, S. (2019) · Brain Pathology · doi:10.1111/bpa.12663 · Cited by 21
Self-citation
Down Syndrome: Genes, Model Systems, and Progress towards Pharmacotherapies and Clinical Trials for Cognitive Deficits
Busciglio, J. A., Capone, G. T., O'Byran, J. P., & Gardiner, K. (2013) · Cytogenetic and Genome Research · doi:10.1159/000354306 · Cited by 20
Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18
Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome
Corrales, A., Parisotto, E. B., Vidal, V., García-Cerro, S., Lantigua, S., Diego, M., Filho, D. W., Sánchez‐Barceló, E. J., Martínez‐Cué, C., & Rueda, N. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.07.022 · Cited by 18
Timing of Treatment with the Flavonoid 7,8-DHF Critically Impacts on Its Effects on Learning and Memory in the Ts65Dn Mouse
Giacomini, A., Stagni, F., Emili, M., Uguagliati, B., Rimondini, R., Bartesaghi, R., & Guidi, S. (2019) · Antioxidants · doi:10.3390/antiox8060163 · Cited by 20
Self-citation
RUN(X) out of blood: emerging RUNX1 functions beyond hematopoiesis and links to Down syndrome
Rozen, E. J., Ozeroff, C. D., & Allen, M. A. (2023) · Human Genomics · doi:10.1186/s40246-023-00531-2 · Cited by 17
Prenatal, but not Postnatal, Curcumin Administration Rescues Neuromorphological and Cognitive Alterations in Ts65Dn Down Syndrome Mice
Rueda, N., Vidal, V., García-Cerro, S., Puente, A., Campa, V. M., Lantigua, S., Narcís, J. O., Bartesaghi, R., & Martínez‐Cué, C. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa207 · Cited by 17
Self-citation
Review of Autism Profiles and Response to Sertraline in Fragile X Syndrome-Associated Autism vs. Non-syndromic Autism; Next Steps for Targeted Treatment
Rajaratnam, A., Potter, L. A., Biag, H. M. B., Schneider, A., Petrasic, I. C., & Hagerman, R. J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.581429 · Cited by 17
Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome
Vidal, V., García-Cerro, S., Martinez, P. M., Corrales, A., Flórez, J., Rueda, N., Sharma, A., & Martínez‐Cué, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.06.031 · Cited by 17
Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome
Stagni, F., Raspanti, A., Giacomini, A., Guidi, S., Emili, M., Ciani, E., Giuliani, A., Bighinati, A., Calzà, L., Magistretti, J., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.012 · Cited by 18
Self-citation
Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome
Roncacè, V., Burattini, C., Stagni, F., Guidi, S., Giacomini, A., Emili, M., Aicardi, G., & Bartesaghi, R. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.017 · Cited by 18
Self-citation
Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome
Emili, M., Stagni, F., Salvalai, M. E., Uguagliati, B., Giacomini, A., Albac, C., Potier, M., Grilli, M., Bartesaghi, R., & Guidi, S. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104874 · Cited by 19
Self-citation
Modulating cognitive deficits and tau accumulation in a mouse model of aging Down syndrome through neonatal implantation of neural progenitor cells
Rachubinski, A. L., Maclean, K. N., Evans, J. R., & Bjugstad, K. B. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.06.013 · Cited by 16
Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer’s Disease
Vidal, V., Puente, A., García-Cerro, S., García‐Unzueta, M. T., Rueda, N., Riancho, J., & Martínez‐Cué, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.613211 · Cited by 16
The atypical Rho GTPase Rnd2 is critical for dentate granule neuron development and anxiety-like behavior during adult but not neonatal neurogenesis
Kerloch, T., Farrugia, F., Bouit, L., Maître, M., Terral, G., Koehl, M., Mortessagne, P., Heng, J. I., Blanchard, M., Doat, H., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01301-z · Cited by 19
Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder
Fuchs, C., Gennaccaro, L., Ren, E., Galvani, G., Trazzi, S., Medici, G., Loi, M., Conway, E., Devinsky, O., Rimondini, R., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107746 · Cited by 17
Self-citation
Commonality in Down and fetal alcohol syndromes
Solzak, J. P., Liang, Y., Zhou, F., & Roper, R. J. (2013) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.23129 · Cited by 16
Mitochondrial regulation of adult hippocampal neurogenesis: Insights into neurological function and neurodevelopmental disorders
Bonzano, S., Dallorto, E., Bovetti, S., Studer, M., & Marchis, S. D. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106604 · Cited by 16
Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease
Sumien, N., Wells, M. S., Sidhu, A., Wong, J. M., Forster, M. J., Zheng, Q.-X., & Kelleher-Andersson, J. A. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02126-3 · Cited by 15
Temporal and brain region‐specific elevations of soluble Amyloid‐β40‐42 in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease
Tallino, S., Winslow, W., Bartholomew, S. K., & Velázquez, R. (2022) · Aging Cell · doi:10.1111/acel.13590 · Cited by 15
Chronic up-regulation of the SHH pathway normalizes some developmental effects of trisomy in Ts65Dn mice
Dutka, T., Hallberg, D. L., & Reeves, R. H. (2014) · Mechanisms of Development · doi:10.1016/j.mod.2014.11.004 · Cited by 15
Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome
Martínez‐Cué, C., & Dierssen, M. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.11.001 · Cited by 15
Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome
Stagni, F., Salvalai, M. E., Giacomini, A., Emili, M., Uguagliati, B., Xia, E., Grilli, M., Bartesaghi, R., & Guidi, S. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.05.005 · Cited by 14
Self-citation
Hypocellularity in the Murine Model for Down Syndrome Ts65Dn Is Not Affected by Adult Neurogenesis
López‐Hidalgo, R., Ballestín, R., Vega, J., Blasco‐Ibáñez, J. M., Crespo, C., Gilabert‐Juan, J., Nácher, J., & Varea, E. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00075 · Cited by 15
Isolation of proflavine as a blocker of G protein-gated inward rectifier potassium channels by a cell growth-based screening system
Kawada, H., Inanobe, A., & Kurachi, Y. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.016 · Cited by 13
Translating molecular advances in Down syndrome and Fragile X syndrome into therapies
Faúndez, V., Toma, I. D., Bardoni, B., Bartesaghi, R., Nižetić, D., de la Torre, R., Kadosh, R. C., Hérault, Y., Dierssen, M., Potier, M., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.03.006 · Cited by 14
Self-citation
The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome
Stagni, F., Uguagliati, B., Emili, M., Giacomini, A., Bartesaghi, R., & Guidi, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-85284-5 · Cited by 13
Self-citation
Can Animal Models Inform on the Relationship between Depression and Alzheimer Disease?
Nyarko, J. N. K., Quartey, M. O., Baker, G. B., & Mousseau, D. D. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743718772514 · Cited by 12
Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy (1H MRS)
Tan, G. M., Beacher, F. D. C. C., Daly, E., Horder, J., Prasher, V., Hanney, M. L., Morris, R. G., Lovestone, S., Murphy, K. C., Simmons, A., et al. (2014) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-6-42 · Cited by 13
The GABA A α5-selective Modulator, RO4938581, Rescues Protein Anomalies in the Ts65Dn Mouse Model of Down Syndrome
Block, A., Ahmed, M. M., Rueda, N., Hernandez, M., Martínez‐Cué, C., & Gardiner, K. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.12.038 · Cited by 13
Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model
Hawley, L. E., Stringer, M., Deal, A. J., Folz, A., Goodlett, C. R., & Roper, R. J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106359 · Cited by 10
“…do exhibit deficient neurological structural phenotypes in brain regions where we found DYRK1A overexpression including during perinatal or early postnatal ages (Baxter et al., 2000; Belichenko et al., 2004; Bianchi et al., 2010; Chakrabarti et al., 2007; Roper et al., 2006b; Stagni et al., 2016).”
GIRK2 Channels in Down Syndrome and Alzheimer’s Disease
Kleschevnikov, A. M. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666221223122110 · Cited by 10
Gene therapy for Down syndrome
Fillat, C., & Altafaj, X. (2012) · Progress in brain research · doi:10.1016/b978-0-444-54299-1.00012-1 · Cited by 11
Enhanced GIRK2 channel signaling in Down syndrome: A feasible role in the development of abnormal nascent neural circuits
Kleschevnikov, A. M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1006068 · Cited by 9
One-carbon pathway metabolites are altered in the plasma of subjects with Down syndrome: Relation to chromosomal dosage
Vione, B., Ramacieri, G., Zavaroni, G., Piano, A., Rocca, G. L., Caracausi, M., Vitale, L., Piovesan, A., Gori, C., Pirazzoli, G. L., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1006891 · Cited by 9
Multisensory gamma stimulation enhances adult neurogenesis and improves cognitive function in male mice with Down Syndrome
Islam, R., Jackson, B., Naomi, M. T., Schatz, B., Tan, N., Murdock, M. H., Park, D. S., Rodrígues-Amorím, D., Jiang, X., Pineda, S. S., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317428 · Cited by 8
Analysis of microisolated frontal cortex excitatory layer III and V pyramidal neurons reveals a neurodegenerative phenotype in individuals with Down syndrome
Alldred, M. J., Pidikiti, H., Ibrahim, K. W., Lee, S. H., Heguy, A., Hoffman, G. E., Roussos, P., Wısnıewskı, T., Węgiel, J., Stutzmann, G. E., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02768-0 · Cited by 8
Reversal of neurodevelopmental impairment and cognitive enhancement by pharmacological intervention with the polyphenol polydatin in a Down syndrome model
Emili, M., Stagni, F., Russo, C. A., Angelozzi, L., Guidi, S., & Bartesaghi, R. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110170 · Cited by 7
Self-citation
Low TGF-β1 plasma levels are associated with cognitive decline in Down syndrome
Grasso, M., Fidilio, A., L’Episcopo, F., Recupero, M., Barone, C., Bacalini, M. G., Benatti, C., Giambirtone, M., Caruso, G., Greco, D., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1379965 · Cited by 7
Pharmacotherapy of Down’s Syndrome: When and Which?
Tayebati, S. K., Cecchi, A., Martinelli, I., Carboni, E., & Amenta, F. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666191114092924 · Cited by 6
Rapid forgetting of social learning in the Ts65Dn mouse model of Down syndrome: New evidence for hippocampal dysfunction.
Powers, B. E., Santiago, N. A., & Strupp, B. J. (2018) · Behavioral Neuroscience · doi:10.1037/bne0000227 · Cited by 5
Molecular Pathways of Down Syndrome Critical Region Genes
Di, F., & Berto, G. E. (2013) · InTech eBooks · doi:10.5772/53000 · Cited by 6
Early chronic fasudil treatment rescues hippocampal alterations in the Ts65Dn model for down syndrome
López‐Hidalgo, R., Ballestín, R., Lorenzo, L., Sánchez-Martí, S., Blasco‐Ibáñez, J. M., Crespo, C., Nácher, J., & Varea, E. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105679 · Cited by 6
Prenatal treatment with preimplantation factor improves early postnatal neurogenesis and cognitive impairments in a mouse model of Down syndrome
Moreau, M., Dard, R., Madani, A., Kandiah, J., Kassis, N., Ziga, J., Castiglione, H., Day, S., Bourgeois, T., Matrot, B., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05245-9 · Cited by 4
Early Chronic Fluoxetine Treatment of Ts65Dn Mice Rescues Synaptic Vesicular Deficits and Prevents Aberrant Proteomic Alterations
Fatemi, S. H., Otte, E. D., Folsom, T. D., Eschenlauer, A. C., Roper, R. J., Aman, J. W., & THURAS, P. D. (2024) · Genes · doi:10.3390/genes15040452 · Cited by 4
Neurodevelopmental Abnormalities in Down Syndrome: Assessing Structural and Functional Deficits
Robinson, J., Chawla, N., Patel, S., Spey, E., McNulty, O., & Kaur, G. (2024) · Cureus · doi:10.7759/cureus.76156 · Cited by 5
Profiling hippocampal neuronal populations reveals unique gene expression mosaics reflective of connectivity-based degeneration in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease
Alldred, M. J., Ibrahim, K. W., Pidikiti, H., Lee, S. H., Heguy, A., Chiosis, G., Mufson, E. J., Stutzmann, G. E., & Ginsberg, S. D. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1546375 · Cited by 4
Fetal Therapy for Down Syndrome: Report of Three Cases and a Review of the Literature.
Baggot, P. J., & Baggot, R. M. (2017) · PubMed · Cited by 4
Down Syndrome
Ruparelia, A., & Mobley, W. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00005-7 · Cited by 4
Deficiency of Adult Neurogenesis in the Ts65Dn Mouse Model of Down Syndrome
Pavel, V., & Alexander, M. (2011) · InTech eBooks · doi:10.5772/24585 · Cited by 4
Assessing the Benefit of Dietary Choline Supplementation Throughout Adulthood in the Ts65Dn Mouse Model of Down Syndrome
Tallino, S., Etebari, R., McDonough, I., Leon, H., Sepulveda, I., Winslow, W., Bartholomew, S. K., Perez, S. E., Mufson, E. J., & Velazquez, R. (2024) · Nutrients · doi:10.3390/nu16234167 · Cited by 3
Early postnatal GABAB antagonist treatment normalizes inhibitory/excitatory balance in neonatal Ts65Dn mice, a genetic model of down syndrome
Jin, J., Doan, J., Fernandez, C., Nguyen, S., Spencer, C., & Kleschevnikov, A. M. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115171 · Cited by 3
Pharmacologically Manipulating Learning and Memory
Fortress, A. M., & Frick, K. M. (2014) · Neuromethods · doi:10.1007/978-1-4939-2159-1_7 · Cited by 3
Down Syndrome
Patterson, D., & Lott, I. T. (2011) · Wiley eBooks · doi:10.1002/9780470015902.a0005711.pub2 · Cited by 3
Loss of Proteostasis and Early-Onset Neurodegeneration in Down Syndrome: From Mechanisms to Interventions
Tramutola, A., Lanzillotta, C., Domenico, F. D., Barone, E., & Marzia Perluigi, A. (2026) · Antioxidants · doi:10.3390/antiox15040520 · Cited by 2
Down syndrome with asymptomatic neuroglial cyst: A case report and review of the literature
Yang, S. D., Lee, S., Lee, D. H., & Hong, Y. H. (2017) · Journal of genetic medicine · doi:10.5734/jgm.2017.14.2.67 · Cited by 2
Down syndrome: a model for chromosome abnormalities
Overk, C., & Mobley, W. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00007-1 · Cited by 4
Dendritic phenotype and proliferation potency in the hippocampal dentate gyrus of the Ts66Yah model of Down syndrome
Emili, M., Stagni, F., Guidi, S., Russo, C. A., Chevalier, C., Duchon, A., Hérault, Y., & Bartesaghi, R. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138156 · Cited by 2
Self-citation
Can Stem Cells Be Used to Enhance Cognition?
Goldberg, N. R. S., & Blurton-Jones, M. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417042-1.00008-5 · Cited by 2
Avances Citogenéticos y Neurobiológicos en el Síndrome de Down
Fernández-Alcaraz, C., & Carvajal, F. (2013) · Anales de Psicología · doi:10.6018/analesps.30.1.132231 · Cited by 2
[Chronic eosinophilic pneumonia presenting as a solitary nodule, suspicious of lung cancer;report of a case].
Matsuoka, T., 上松, 浩., Iwakiri, S., & Itoi, K. (2013) · PubMed · Cited by 2
Elevated mitochondrial metabolism in Down syndrome iPSCs reduces commitment to neuroectoderm
Chaklader, M., Bomfim, G. H. S., Zhu, J., Jeju, N., Nguyen, T., Duan, Y., Niemeyer, B. F., Espinosa, J. M., Rosado-Olivieri, E., Lin, W., et al. (2026) · EMBO Reports · doi:10.1101/2025.05.09.653211 · Cited by 1
Effects of vitamin C on inhalation anesthetic isoflurane-induced developmental, neuronal apoptosis in neonatal rats
SHUAI, Y.-F., Wang, M.-Q., Xiong, L.-Q., Liu, L., Luo, Y.-H., & Peng, T.-S. (2014) · Bangladesh Journal of Pharmacology · doi:10.3329/bjp.v9i4.20534 · Cited by 1
Down syndrome, health and disability : a population-based case record and follow-up study
Määttä, T. (2011) · Cited by 1
Modulation of the dentate area’s postnatal neurogenesis in rats and mice: behavioral consequences and the role of genotypes
Timoshenko, T. V., Boyarshinova, O. S., Perepelkina, O. V., Полетаева, И. И., Павлова, Г. В., & Revishchin, A. V. (2012) · Cited by 1
Down Syndrome
Bowman, A. B., Ess, K. C., Kumar, K. K., & Summar, K. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397267-5.00130-8 · Cited by 1
Chloride transporters in physiological brain development and neurodevelopmental disorders: The case of the Down syndrome
Savardi, A., Ziogas, I., Bolla, M., & Cancedda, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815318-5.00021-2 · Cited by 1
Down Syndrome and Cell Therapy: A Review
Salamt, N., Idrus, R. H., & Nasri, N. W. M. (2021) · Sains Malaysiana · doi:10.17576/jsm-2021-5005-17 · Cited by 1
Loss of the Histone Demethylase Phf8 Is Compatible With Development but Confers Resilience to Anxiety and Depression
Walsh, R. M. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
P.4.07 Prenatal therapy with a BDNF mimetic elicits a widespread rescue of neurogenesis in a mouse model of Down syndrome
Uguagliati, B., Stagni, F., Giacomini, A., Emili, M., Guidi, S., & Bartesaghi, R. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.01.097
Self-citation
Does Down syndrome occur more frequently in mothers with advanced age for patients diagnosed at Rwanda Center for Medical Genetics
Hitayezu, J. (2016)
Long-lasting effects of transient, perinatal fluoxetine exposure on cell proliferation in the dentate gyrus of micePreprint
Spanswick, S. C., Chrusch, M. J., Kiryanova, V., & Dyck, R. H. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/778951
Defective engram allocation contributes to impaired fear memory performance in Down syndromePreprint
Fernández‐Blanco, Á., Zamora‐Moratalla, A., Sabariego-Navarro, M., & Dierssen, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.11.523460
Promising therapeutic approaches in Down Syndrome: addressing parents' doubts
Monteiro, S. A. P., Soares, S., Matos, I. V., Machado, L. A. F., Mendes, D. G. P., & Prior, C. (2023) · Pediatric Oncall · doi:10.7199/ped.oncall.2024.7
Down Syndrome: Progress in Defining Pathogenesis and Treatments for Neurodevelopmental Deficits and Alzheimer’s Disease
Bartesaghi, R., Chen, X., Johnstone, A. D., Das, U., & Mobley, W. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_19
Self-citation
Additional file 1 of Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease
Sumien, N., Wells, M. S., Sidhu, A., Wong, J. M., Forster, M. J., Zheng, Q.-X., & Kelleher-Andersson, J. A. (2021) · Figshare · doi:10.6084/m9.figshare.13565772
Étude du neurodéveloppement et de l'infertilité masculine chez différents modèles murins de Trisomie 21
Dard, R. (2024) · theses.fr (ABES) · doi:10.70675/a4b3d243zd280z49b8zb850z350254dce74c
Effects of Fluoxetine on Cognitive Functioning in Children with Down Syndrome: A Prospective Open-Label Exploratory Study of Safety and Efficacy
Scala, I., Bravaccio, C., Marino, M., Scicolone, O., Maffettone, V., Riccio, M. P., Terrone, G., Cattaneo, D., Clementi, E., Bartesaghi, R., et al. (2026) · Journal of Child and Adolescent Psychopharmacology · doi:10.1177/10445463261458603
Self-citation
Fasudil induces anti-inflammatory transcriptomic changes and increased proliferation in human trisomy 21 neural progenitor cells
Baxter, L. L., Lee, S., Fuentes, K., Mosley, I. A., Raymond, J. D., Guedj, F., Zhou, D., Slonim, D. K., Glotfelty, E. J., Tweedie, D., et al. (2026) · Biology Open · doi:10.1242/bio.062807
DHA-H and HPA restore impaired neurogenic phenotypes and BDNF-TrkB signaling in Ts65Dn neurospheres and hippocampus
Castroflorio, E., Cabot, J., Suau, M., Santillan, A. J., Gomez, G. V., Fernández‐García, P., Lladó, V., Escribá, P. V., & Torres, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.120021
Pharmacological Rescue of Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome
Stagni, F. (2014) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/6201

Authors: Bianchi, P., Ciani, E., Guidi, S., Trazzi, S., Felice, D., Grossi, G., Fernandez, M., Giuliani, A., Calza, L., & Bartesaghi, R.
Affiliations: University of Bologna (IT)
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
Corresponding author: Bartesaghi, R.
ORCID: Ciani, E.
Guidi, S.
Trazzi, S.
Giuliani, A.
Bartesaghi, R.
Venue: Journal of Neuroscience
Publisher: Society for Neuroscience
Published: 2010-06-30
Volume: 30
Issue: 26
Pages: 8769-8779
ISSN: 0270-6474 (ISSN-L)
1529-2401
DOI: 10.1523/jneurosci.0534-10.2010
PMC: PMC6632890
OpenAlex: W2086398583
Cited by: 188
References: 62
Citations by year: 2026: 5 · 2025: 6 · 2024: 11 · 2023: 5 · 2022: 8 · 2021: 8 · 2020: 7 · 2019: 13 · 2018: 9 · 2017: 20 · 2016: 10 · 2015: 11 · 2014: 21 · 2013: 16 · 2012: 25
FWCI: 17.18
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Neuroscience (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords: Down syndrome, Ts65Dn mouse model, fluoxetine, neurogenesis, serotonin, 5-HT1A receptor, brain-derived neurotrophic factor, dentate gyrus, subventricular zone, striatum, neocortex, cell proliferation, contextual fear conditioning, hippocampal-dependent memory, intellectual disability
MeSH terms: Animals, Animals, Newborn, Brain, Cognition, Disease Models, Animal, Down Syndrome, Fluoxetine, Memory Disorders, Mice, Transgenic, Neurons, Serotonin, Stem Cells, Time Factors, Selective Serotonin Reuptake Inhibitors, Brain-Derived Neurotrophic Factor, Receptor, Serotonin, 5-HT1A, Cell Proliferation, Mice, Neurogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks